
Please try another search
Sinovac Biotech Ltd., through its subsidiaries, operates as a biopharmaceutical company that focuses on the research, development, manufacture, and commercialization of vaccines against human infectious diseases in China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products, include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella; pneumococcal polysaccharide vaccine; quadrivalent influenza vaccine; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine; and rubella vaccine. Sinovac Biotech Ltd. was formerly known as Net-Force System Inc. and changed its name to Sinovac Biotech Ltd. in October 2003. The company was incorporated in 1999 and is based in Beijing, China.
Name | Age | Since | Title |
---|---|---|---|
Chiang Li | - | - | Chairman |
Shuge Jiao | - | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review